Redeye Feed

2023-03-21 07:56:00 Nepa - Negative share-price development likely to turn when cost savings are realized throughout 2023

2023-03-20 08:50:00 Energy Save - Accelerates the business plan

2023-03-17 07:46:00 Amniotics - Taking the Next Step with PulmoStem

2023-03-15 09:00:00 Redeye Initiates Coverage of Scandinavian ChemoTech

2023-03-14 07:47:00 Acuvi - Solid growth prospects

2023-03-13 14:18:00 Integrum Q3 - On track, but still a challenging market outlook

2023-03-13 10:02:00 Systemair - Favorable Tailwinds

2023-03-13 07:18:00 Zordix - Increased focus on own IP’s with launch of Maximum Entertainment

2023-03-10 08:15:00 Neonode: Good Q4 report, Cash Balance Strengthened, and Lawsuit Success More Likely, But Less Money

2023-03-08 14:51:00 Xspray Pharma - A year with pivotal potential ahead

2023-03-07 08:43:00 Fantasma Games - An emerging growth story

2023-03-07 08:00:00 TH1NG Q4 2022 - Continuous expansion

2023-03-06 07:30:00 Modelon - Major Impact in H1 2023

2023-03-03 13:26:00 Faron Pharmaceuticals Annual report - A potential game-changer

2023-03-03 09:16:00 Herantis H2 2022 - Important progress

2023-03-03 08:05:00 Infracom - Acquiring Connect and Datatal

2023-03-02 08:36:00 Heliospectra Q4 2022 - Positive outlook and permanent CEO appointed

2023-03-02 07:47:00 W5 Solutions - Strong growth outlook for 2023

2023-03-02 07:28:00 Norse Impact - Preparing for the future

2023-03-02 07:20:00 Efecte - Solid Guidance in Uncertain Market

2023-03-02 07:10:00 Seamless Distribution Systems Q4 - Not as weak as the numbers indicate

2023-03-01 15:25:00 Media and Games Invest - Spring cleaning

2023-03-01 14:48:00 RLS Global Q4 2022 - No surprises – but expectations of an eventful 2023

2023-03-01 14:40:00 Inhalation Sciences Q4 2022 - In line with our expectations

2023-03-01 11:26:00 Better Collective - Growing recurring revenue

2023-03-01 10:58:00 Penneo - 2023 guidance implies continued solid growth

2023-03-01 10:52:00 Fluoguide Q4 2022 - Slightly shifted timelines but equity story remains unchanged

2023-03-01 10:46:00 Gasporox - Managed for long-term value creation

2023-03-01 10:40:00 Lipigon Q4 2022 - Rights issue and Progress with Lipisense

2023-02-28 13:35:00 Nexstim H2 2022 - Slight miss – but profitability in sight

2023-02-28 07:40:00 LIDDS - Setting sail

2023-02-27 13:05:00 Alzecure - Q4 comment

2023-02-27 12:56:00 OXE Marine - Air pocket in Q4

2023-02-27 09:35:00 Imint - Customer cost-cutting programs hurt sales in Q4 2022

2023-02-27 08:48:00 Idogen Q4 2022 - The future is contingent on funding

2023-02-27 08:43:00 Northbaze Q4 2022 - Review

2023-02-27 08:30:00 Calliditas February 2023 Update - The proof is in the pudding

2023-02-27 08:17:00 Beyond Frames - Lower visibility regarding coming games titles

2023-02-27 08:15:00 I-Tech - Q4 Review – Raising the Bar

2023-02-27 08:09:00 Binero - Steps in the right direction

2023-02-27 07:59:00 Sensys Gatso - Strong Momentum Into 2023

2023-02-27 07:55:00 Infracom - Emerging synergies

2023-02-27 07:48:00 Fragbite Group - Scaling up its organization

2023-02-27 07:37:00 SaveLend Group - An attractive entry point

2023-02-27 07:30:00 Paxman Q4’22 - Continued positive outlook

2023-02-27 07:24:00 Strax - Execution the on strategic plan

2023-02-24 14:30:00 Saniona Q4 2022 - Transformational year

2023-02-24 09:45:00 IRLAB Therapeutics Q4 2022 - Still Plenty of Value

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Redeye

Prenumeration

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden